Optical projection imaging system and method for automatically detecting cells with molecular marker compartmentalization associated with malignancy and disease

• US 20030031352A1
• Filed: 05/14/2002
• Published: 02/13/2003
• Est. Priority Date: 08/10/2001
• Status: Active Grant

• Current Assignee: VisionGate, Inc.
• Original Assignee: VisionGate, Inc.
• Inventors: Chu, Chee-Wui, Webster, Robert W., Nelson, Alan C.
• Granted Patent: US 6,636,623 B2
• Time in Patent Office: Days
• US Class Current: 382/131
• CPC Class Codes: G01N 15/1433 using image recognition
• CPC Class Codes: G01N 2015/1006 for cytology
• CPC Class Codes: G01N 2223/419 computed tomograph
• CPC Class Codes: G01N 23/046 using tomography, e.g. computed tomography [CT]
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G06T 2207/10152 Varying illumination
• CPC Class Codes: G06T 2207/30024 Cell structures in vitro; Tissue sections in vitro
• CPC Class Codes: G06T 7/0012 Biomedical image inspection
• CPC Class Codes: G06V 20/69 Microscopic objects, e.g. biological cells or cellular parts

Abstract

A system and method for rapidly detecting cells associated with malignancy and disease using molecular marker compartmentalization includes an optical tomography (OT) or a flow optical tomography (FOT) instrument capable of producing various optical projection images (or shadowgrams) containing accurate density information from a cell or cells labeled with tagged molecular probes or stains, a computer and software to analyze and reconstruct the projection images into a multi-dimensional data set, and automated feature collection and object classifiers. The system and method are particularly useful in the early detection of cancers such as lung cancer using cells from sputum or cheek scrapings and cervical/ovarian cancer using a cervical scraping, and the system can be used to detect rare cells in specimens including blood.

Claims

19. A method for the detection of cells with molecular marker compartmentalization associated with malignancy and disease including a cancer, the method comprising the steps of:

a) obtaining a cell sample having a plurality of cells and suspending the plurality of cells in a solution;

b) if required, fixing the plurality of cells of the cell sample;

c) labeling at least one molecular marker in the plurality of cells with tagged molecular probes or stains;

d) illuminating at least one cell of the plurality of cells with at least one point source of light;

e) obtaining at least one projection image through the at least one cell with a digital array detector;

f) compensating the at least one projection image for variations in illumination;

g) analyzing the at least one projection image to detect at least one labeled molecular marker;

h) analyzing the location of the at least one molecular marker in two-dimensional (2D) space within the at least one cell;

i) measuring compartmentalization of the at least one labeled molecular marker by using the densitometric and location features; and

j) analyzing compartmentalization of the at least one labeled molecular marker with at least one classifier for the detection of malignancy and/or disease associated molecular marker-compartmentalization.

1. A method for the detection of cells with molecular marker compartmentalization associated with malignancy and/or disease including a cancer, the method comprising the steps of:

a) obtaining a cell sample having a plurality of cells and suspending the plurality of cells in a solution;

b) if required, fixing the plurality of cells of the cell sample;

c) labeling at least one molecular marker in the plurality of cells with tagged molecular probes or stains;

d) illuminating at least one cell of the plurality of cells with at least one point source of light;

e) obtaining at least two different projection images through the at least one cell with a digital array detector;

f) compensating the at least two projection images for variations in illumination;

g) analyzing the at least two projection images to detect at least one labeled molecular marker having densitometric and location features;

h) analyzing the location of the at least one molecular marker within the at least one cell;

i) measuring compartmentalization of the at least one labeled molecular marker by using the densitometric and location features; and

j) analyzing compartmentalization of the at least one labeled molecular marker with at least one classifier for the detection of malignancy and/or disease associated molecular marker-compartmentalization.

2. The method of claim 1, wherein the step of obtaining at least two different projection images further comprises operating an optical tomography (OT) system to obtain the at least two projection images.

3. The method of claim 2, wherein the OT system comprises a Flow Optical Tomography (FOT) system.

4. The method of claim 1, wherein the cell sample comprises at least one isolated specimen selected from the group consisting of sputum, bronchial-alveolar lavage, buccal scrapes, urine, cervical scrapes and swabs, nipple aspirates, nipple lavage, stool, fine needle aspirates from target organs and blood.

5. The method of claim 1, further comprises the step of stripping cytoplasm from the plurality of cells.

6. The method of claim 1, wherein the cancer is selected from the group consisting of cancer of the lung, bladder, uterine cervix, breast, colon, rectum, prostate, ovary and blood cells.

7. The method of claim 1, wherein the molecular probes are selected from the group consisting of antibodies, specific binding proteins, lectins, nucleic acid probes tagged with chromophores, fluorophores, enzymes that can generate chromophores and enzymes that can generate fluorophores.

8. The method of claim 1, wherein the at least one labeled molecular marker is selected from the group consisting of pRb, p53/53BP1, E2F, PTEN, SAM68, BRCA1, c-myc and methyl CpG.

9. The method of claim 1, wherein the at least one labeled molecular marker demonstrates different compartmentalization between cells or cell nuclei taken from individuals with cancer and cells or cell nuclei taken from individuals without cancer.

10. The method of claim 1, further comprising the step of using image analysis to reconstruct boundary surfaces of at least one cellular compartment within which at least one labeled molecular marker occurs.

11. The method of claim 1, wherein the step of measuring compartmentalization further comprises the step of analyzing texture of density features formed by the at least one labeled molecular marker located within coinciding bounding surfaces located within the at least two projection images.

12. The method of claim 11, further comprising the step of comparing the boundary surfaces within the at least two projection images to determine a set of coinciding boundary surfaces between the at least two projection images.

13. The method of claim 1, wherein the step of measuring compartmentalization further comprises the step of determining co-localization of at least two labeled markers in reconstructed 3D space.

14. The method of claim 1, wherein the step of measuring compartmentalization further comprises the step of determining co-localization of at least two labeled markers in 2D space.

15. The method of claim 1, wherein the step of measuring compartmentalization further comprises the step of analyzing texture of density features of at least two labeled markers in relationship to each other.

16. The method of claim 11, wherein the texture of density features is selected from the group consisting of optical density (OD) variance, OD skewness, OD range, OD average, OD maximum, density of light spots, high average distance, mid/high average distance, correlation, homogeneity, entropy, fractal dimension, punctateness, nearest neighbor analysis, connected components, nearest neighbor analysis and harmonics in spatial density frequency space.

17. The method of claim 13, wherein the step of measuring compartmentalization further comprises the step of detecting methylated CpG islands in promoter regions of tumor suppressor genes by co-localizing methyl CpG and DNA sequences specific for the promoter region of the target genes that are labeled with methyl CpG binding proteins and nucleic acid probes.

18. The method of claim 14, wherein the step of measuring compartmentalization further comprises the step of detecting methylated CpG islands in promoter regions of tumor suppressor genes by co-localizing methyl CpG and DNA sequences specific for the promoter region of the target genes that are labeled with methyl CpG binding proteins and nucleic acid probes.

20. The method of claim 19, wherein the step of obtaining at least one projection image further comprises operating an optical tomography (OT) system to obtain the at least two projection images.

21. The method of claim 20, wherein the OT system comprises a Flow Optical Tomography (FOT) system.

22. The method of claim 19, wherein the cell sample comprises at least one isolated specimen selected from the group consisting of sputum, bronchial-alveolar lavage, buccal scrapes, urine, cervical scrapes and swabs, nipple aspirates, nipple lavage, stool, fine needle aspirates from target organs and blood.

23. The method of claim 19, further comprises the step of stripping cytoplasm from the plurality of cells.

24. The method of claim 19, wherein the cancer is selected from the group consisting of cancer of the lung, bladder, uterine cervix, breast, colon, rectum, prostate, ovary and blood cells.

25. The method of claim 19, wherein the molecular probes are selected from the group consisting of antibodies, specific binding proteins, lectins, nucleic acid probes tagged with chromophores, fluorophores, enzymes that can generate chromophores and enzymes that can generate fluorophores.

26. The method of claim 19, wherein the at least one labeled molecular marker is selected from the group consisting of pRb, p53/53BP1, E2F, PTEN, SAM68, BRCA1, c-myc and methyl CpG.

27. The method of claim 19, wherein the at least one labeled molecular marker demonstrates different compartmentalization between cells or cell nuclei taken from individuals with cancer and cells or cell nuclei taken from individuals without cancer.

28. The method of claim 19, further comprising the step of using image analysis to reconstruct boundary surfaces of at least one cellular compartment within which at least one labeled molecular marker occurs.

29. The method of claim 26, wherein texture analysis includes but is not limited to optical density (OD) variance, OD skewness, OD range, OD average, OD maximum, density of light spots, high average distance, mid/high average distance, correlation, homogeneity, entropy, fractal dimension, punctateness, nearest neighbor analysis, connected components, nearest neighbor analysis and harmonics in spatial density frequency space.

30. The method of claim 29, wherein the step of measuring compartmentalization further comprises the step of detecting methylated CpG islands in promoter regions of tumor suppressor genes by co-localizing methyl CpG and DNA sequences specific for the promoter region of the target genes that are labeled with methyl CpG binding proteins and nucleic acid probes.

27-1. The method of claim 19, wherein the step of measuring compartmentalization further comprises the step of determining co-localization of at least two labeled markers in 2D space.

28-2. The method of claim 19, wherein the step of measuring compartmentalization further comprises the step of a nalyzing texture of density features of at least two labeled markers in relationship to each other.